A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

Cyrill A. Rentsch, George N. Thalmann, Ilaria Lucca, Maciej Kwiatkowski, Grégory J. Wirth, Räto T. Strebel, Daniel Engeler, A Pedrazzini, Clemens Hüttenbrink, Wolfgang Schultze‐Seemann, Raimund Torpai, Lukas Bubendorf, Andreas Wicki, Beat Roth, Piet Bosshard, Heike Püschel, Daniel T. Boll, Lukas J. Hefermehl, Florian Roghmann, Michael Gierth, Karin Ribi, Simon Schäfer, Stefanie Hayoz